Blood test for early detection of prostate cancer

Prostate cancer is the second most common cancer in the world and the 5th leading cause of cancer deaths among men. WHO estimates 1.4 million incident cases worldwide in 2020. More than 350,000 men are estimated to die during the year.

  • 100 %

    More cases of aggressive cancers found

  • 50 %

    Fewer unnecessary biopsies

  • 17-28 %

    Reduced healthcare costs

History and development

A3P Biomedical AB was founded in 2020. The development of the company’s leading product Stockholm3, a clinically and commercially validated blood test for early detection of aggressive prostate cancer, began much earlier. Several leading healthcare providers in Sweden and Norway have replaced PSA with Stockholm3. Synlab, Europe’s largest laboratory chain, has started a roll-out in Europe.